Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's lymphoma

Onkologie

Volumn 31, Issue 1-2, 2008, Pages 49-51

  Schnell, R ^a,b   Dietlein, M ^a   Schomacker K ^a   Kobe, C ^a   Borchmann, P ^a   Schicha, H ^a   Hallek, M ^a   Engert, A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Hodgkin's lymphoma; Ibritumomab tiuxetan; Immunotherapy; Yttrium 90

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; GEMCITABINE; IBRITUMOMAB TIUXETAN; INDIUM 111; RITUXIMAB; VINBLASTINE;

AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPHOCYTE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 39149129610     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111758     Document Type: Article

References (14)

1. Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, Poppema S, Harris M, Franssila K, van Krieken J, Marafioti T, Anagnostopoulos I, Stein H: Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999;17(3):776-83.
2. Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, Vassilakopoulos TP, Mesina O, Herling M, Angelopoulou MK, Giardini R, Chilosi M, Kittas C, McLaughlin P, Rodriguez MA, Romaguera J, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH: CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol 2002;20(5):1278-87.
3. Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ: Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101(11):4285-9.
4. Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F, Driessen C, Rudiger T, Muller-Hermelink K, Diehl V, Engert A: Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003;101(2):420-4.
5. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT Jr., Jones D, Abruzzo LV, Medeiros LJ: A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98(2):310-4.
6. Klimm B, Schnell R, Diehl V, Engert A: Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica 2005;90(12):1680-92.
7. Schnell R, Borchmann P: SGN-30 (Seattle genetics). Curr Opin Mol Ther 2006;8(2):164-72.
8. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T, Graziano R, Blanset D, Yellin M, Fischkoff S, Assad A, Borchmann P: Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25(19):2764-9.
9. Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis LD, Behnke D, Wickenhauser C, Schiller P, Diehl V, Engert A: Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 2002;100(9):3101-7.
10. Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, Sek A, Konig J, Bauer S, Kloft M, Pfreundschuh M: Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 2001;7(7):1873-81.
11. Schnell R, Borchmann P, Staak JO, Schindler J, Ghetie V, Vitetta ES, Engert A: Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 2003;14(5):729-36.
12. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Dürkop H, Aversa F, Corneli P, Pizzolo G, et al.: Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992;339(8803):1195-6.
13. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20(10):2453-63.
14. Younes A, Jorge ER, McLaughlin P, Wong F: A pilot study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in patients with relapsed and refractory classical Hodgkin lymphoma (HL): delivering cross fire radiation by targeted reactive B cells in the microenvironment. Blood 2005;106(11):abstr 4791.